Success Metrics

Clinical Success Rate
100.0%

Based on 8 completed trials

Completion Rate
100%(8/8)
Active Trials
0(0%)
Results Posted
25%(2 trials)

Phase Distribution

Ph phase_3
1
11%
Ph phase_1
6
67%
Ph phase_2
1
11%

Phase Distribution

6

Early Stage

1

Mid Stage

1

Late Stage

Phase Distribution8 total trials
Phase 1Safety & dosage
6(75.0%)
Phase 2Efficacy & side effects
1(12.5%)
Phase 3Large-scale testing
1(12.5%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

8 of 8 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

9

all time

Status Distribution
Completed(8)
Other(1)

Detailed Status

Completed8
unknown1

Development Timeline

Analytics

Development Status

Total Trials
9
Active
0
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 16 (75.0%)
Phase 21 (12.5%)
Phase 31 (12.5%)

Trials by Status

completed889%
unknown111%

Recent Activity

0 active trials
Showing 5 of 9
completedphase_3

A Study to Evaluate the Efficacy and Safety of Lumacaftor in Combination With Ivacaftor in Subjects With CF, Homozygous for the F508del-CFTR Mutation

NCT02514473
completedphase_2

Study of the Effect of VX-770 on Hyperpolarized Helium-3 Magnetic Resonance Imaging in Subjects With Cystic Fibrosis and the G551D Mutation

NCT01161537
unknown

VX-770 Expanded Access Program

NCT01381289
completedphase_1

Drug-Drug Interaction Study of VX-770 and VX-809 in Healthy Subjects

NCT01216046
completedphase_1

Study of VX-770 in Subjects With Moderate Hepatic Impairment and in Matched Healthy Subjects

NCT01208285
View all 9 trials

Clinical Trials (9)

Showing 9 of 9 trials
NCT02514473Phase 3

A Study to Evaluate the Efficacy and Safety of Lumacaftor in Combination With Ivacaftor in Subjects With CF, Homozygous for the F508del-CFTR Mutation

Completed
NCT01161537Phase 2

Study of the Effect of VX-770 on Hyperpolarized Helium-3 Magnetic Resonance Imaging in Subjects With Cystic Fibrosis and the G551D Mutation

Completed
NCT01381289

VX-770 Expanded Access Program

Unknown
NCT01216046Phase 1

Drug-Drug Interaction Study of VX-770 and VX-809 in Healthy Subjects

Completed
NCT01208285Phase 1

Study of VX-770 in Subjects With Moderate Hepatic Impairment and in Matched Healthy Subjects

Completed
NCT01153542Phase 1

Study of VX-770 on Desipramine

Completed
NCT01018368Phase 1

Study of VX-770 and Rifampin in Healthy Male Subjects

Completed
NCT01060566Phase 1

Study of VX-770 on Midazolam and Rosiglitazone and the Effect of Fluconazole on VX-770

Completed
NCT00966602Phase 1

Drug-Drug Interaction Study of VX-809 and VX-770 in Healthy Subjects

Completed

All 9 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
9